

**RECORDATI: UPDATE ON THE EXECUTION OF THE SHARE BUY-BACK PROGRAM**

Milan, 5<sup>th</sup> February 2025 – Within the Recordati’s share buy-back program communicated to the market on 11<sup>th</sup> November 2024 and initiated on 12<sup>th</sup> November 2024, as per authorization granted by the Shareholders’ Meeting held on 22<sup>nd</sup> April 2024, with the object of the servicing of current stock option / performance shares plans in favour of the Recordati Group’s management or share-based incentive plans that might be approved by the Company in the future, the Company communicates the following purchase transactions of Recordati shares pursuant to art. 2, paragraph 3, of the EU Delegated Regulation 2016/1052/EU, on the basis of the information provided by UBS Europe SE as intermediary in charge of executing, in full independency, the share buy-back program on behalf of the Company.

Aggregate details of daily transactions made from 27<sup>th</sup> to 31<sup>st</sup> January 2025 in Recordati ordinary shares (ISIN IT0003828271) are as follows:

<b>SUMMARY OF PURCHASE TRANSACTIONS</b>				
<b>Date</b>	<b>Type of Transaction</b>	<b>Quantity</b>	<b>Weighted average price (Euro)</b>	<b>Exchange</b>
27/01/2025	Purchase	5.041	56,0592	MTA
<b>TOTAL</b>		<b>5.041</b>	<b>56,0592</b>	

The details of all the purchase transactions carried out in the period indicated above are reported in the following pages.

On 31<sup>st</sup> January 2025, the Company held no. 2,656,699 treasury shares which amount to 1.270% of the current share capital.

***Recordati** is an international pharmaceutical group listed on the Italian Stock Exchange (XMIL: REC), with roots dating back to a family-run pharmacy in Northern Italy in the 1920s. We are uniquely structured to provide treatments across specialty and primary care, and rare diseases. Our fully integrated operations span clinical development, chemical and finished product manufacturing, commercialization and licensing. We operate in approximately 150 countries across EMEA, the Americas and APAC with over 4,450 employees. We believe that health is a fundamental right, not a privilege. Today, our purpose of “unlocking the full potential of life” aims at empowering individuals to live life to the fullest, whether addressing common health challenges or the rarest.*

**RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.**

Registered Office  
Via Matteo Civitali, 1  
20148 Milano, Italy  
Tel. +39 02 487871  
Fax +39 02 40073747  
www.recordati.com

Share Capital € 26.140.644,50 fully paid-up  
Milano, Monza, Brianza and Lodi Comp. Reg. No. 00748210150  
Tax Code/VAT No. 00748210150  
Milano R.E.A. No. 401832

Company subject to the Management and Coordination Activity of Rossini Luxembourg S.à.r.l

**Investor Relations**

Eugenia Litz  
+44 7824 394 750  
[investorelations@recordati.it](mailto:investorelations@recordati.it)

Gianluca Saletta  
+39 348 979 4876  
[investorelations@recordati.it](mailto:investorelations@recordati.it)

**Media Relations**

ICR Healthcare US:  
Alexis Feinberg  
[+1 203 939 2225](tel:+12039392225)  
[recordatiuspr@westwicke.com](mailto:recordatiuspr@westwicke.com)

UK, Europe & Rest of World:  
Jessica Hodgson  
+44 7561 424 788  
[recordati@consilium-comms.com](mailto:recordati@consilium-comms.com)

Attachment: daily details of transactions

<b>Data</b>	<b>Orario (GMT)</b>	<b>Valuta</b>	<b>Mercato</b>	<b>Prezzo</b>	<b>Quantità</b>
27/01/2025	08:10:35	EUR	MTA	56,2000	509
27/01/2025	08:48:14	EUR	MTA	56,0000	510
27/01/2025	08:48:14	EUR	MTA	56,0000	631
27/01/2025	08:49:53	EUR	MTA	55,9500	425
27/01/2025	08:49:53	EUR	MTA	55,9500	164
27/01/2025	10:20:56	EUR	MTA	56,1000	515
27/01/2025	12:14:01	EUR	MTA	56,2000	584
27/01/2025	12:20:18	EUR	MTA	56,0000	123
27/01/2025	12:20:18	EUR	MTA	56,0000	392
27/01/2025	12:20:18	EUR	MTA	56,0000	610
27/01/2025	13:32:16	EUR	MTA	56,1000	578